1357191-82-2Relevant academic research and scientific papers
Practical Preparation of a 1,3,5-Trisubstituted Pyridazin-4(1 H)-one Using Selective C1 Unit Insertion and Cyclization
Suzuki, Akihiro,Fukuda, Naohiro,Kajiwara, Takeshi,Ikemoto, Tomomi
, p. 484 - 492 (2019/02/14)
A novel and practical preparation of the selective phosphodiesterase 10A (PDE10A) inhibitor 1 having the core moiety of a 1,3,5-trisubstituted pyridazin-4(1H)-one has been achieved. The facile preparation of 1 in 42% overall yield involves the following key features: (1) the finding that filling the headspace of the reaction vessel with Ar gas and controlling the flow rate of the gas were found to be important to complete the substitution of an aryl iodide with pyrazole; (2) synthesis of a 3-acetyl-5-methoxy-substituted pyridazin-4(1H)-one via regioselective dimethylaminomethylenation of a diazo compound and simultaneous cyclization; and (3) regioselective ring formation of a 1,5-disubstituted pyrazole through reaction of a dimethylaminomethylene group with phenylhydrazine. In addition, an alternative synthesis of 1 via selective alkylation of 1-phenylpyrazole has been discovered.
PRODUCTION METHOD OF PYRIDAZINONE COMPOUNDS
-
Paragraph 0200, (2014/09/03)
The present invention provides an industrially advantageous method of producing a pyridazinone compound. The present invention relates to the following method of producing a pyridazinone compound: Formula (II), (IIIa), (IV) or (IV ), Formula (IIIb), (Vb) or (V b), Formula (VI), (I) or (I ). wherein each symbol is as described in the specification.
RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS
-
Paragraph 0388, (2013/03/26)
The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification.
HETEROCYCLIC COMPOUND
-
Paragraph 0468; 0469, (2013/06/27)
The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.
